Home » NIAID to Test Tarvacin for Antiviral Potential
NIAID to Test Tarvacin for Antiviral Potential
Peregrine Pharmaceuticals and the National Institute of Allergy and Infectious Disease (NIAID) have agreed to a collaboration in which NIAID's testing laboratories will screen Peregrine's Anti-Phospholipid Therapy agents, including Tarvacin, for activity against a broad spectrum of enveloped viral pathogens of health and bioterrorism concern.
Virus types to be screened as part of the collaboration potentially include herpes viruses, respiratory viruses, pox viruses, hepatitis B and C, Papillomavirus and viruses of biodefense concern including Pichinde, Yellow Fever, West Nile and Dengue.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May